(Q36184260)

12 August 2017

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual (English)

1 reference

12 August 2017

E M Wever

1

1 reference

12 August 2017

J Hugosson

2

1 reference

12 August 2017

E A M Heijnsdijk

3

1 reference

12 August 2017

C H Bangma

4

1 reference

12 August 2017

G Draisma

5

1 reference

12 August 2017

H J de Koning

6

1 reference

12 August 2017

language of work or name

English

0 references

publication date

17 July 2012

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

107

1 reference

12 August 2017

778-784

1 reference

12 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2012.317

12 August 2017

0 references

cites work

How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Impact of comorbidity on survival among men with localized prostate cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

American Cancer Society guideline for the early detection of prostate cancer: update 2010

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Screening and prostate-cancer mortality in a randomized European study

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Screening for prostate cancer in U.S. men ACPM position statement on preventive practice

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

20-year outcomes following conservative management of clinically localized prostate cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam Cancer Registry

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Predicting utility ratings for joint health States from single health States in prostate cancer: empirical testing of 3 alternative theories.

2 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.317

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.317

Including the quality-of-life effects in the evaluation of prostate cancer screening: expert opinions revisited?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.317

Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.317

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.317

Quality of life after radical prostatectomy or watchful waiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.317

Utilities for prostate cancer health states in men aged 60 and older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.317

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425982

Patients’ perceptions of the side-effects of prostate cancer treatment—A qualitative interview study

21 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22805324

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Gleason score, age and screening: Modeling dedifferentiation in prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22805324

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22805324

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2012.317

1 reference

12 August 2017

1 reference

12 August 2017

1 reference